NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. ( ALXN ) today reported results from the PROTECT Study, a Phase 2/3 registration trial of eculizumab (Soliris ® ) for the prevention of delayed graft function (DGF) after kidney ... Yahoo! Finance UK and Ireland, 3 weeks ago
Upcoming SlideShare Loading in … 5 1. JAMES R. COUGHLIN, Ph.D. CFS COUGHLIN & ASSOCIATES Consultants in Food / Nutritional / Chemical Toxicology and Safety 8 Camillo, Aliso Viejo, CA 92656 Tel. (949) 916-6217 E-mail: firstname.lastname@example.org ...SlideShare.net, 1 month ago
on your WebpageAdd Widget >Get your members hooked!